CRISPR Delivery Challenges and Applications in Pharma
Add bookmark
We respect your privacy, by clicking "Download Your Copy" you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. You have the right to object. In addition, you will receive our e-newsletter, including information on related online learning opportunities. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here.
CRISPR is now one of the most affordable forms of gene editing causing a boom in R&D over the last few years. However, the technique does have its limitations which include maintaining end to end control on genetic manipulation, avoiding off targets effects and pathway recovery post double strand break.
Ahead of the 2017 CRISPR summit Javier Terriente, CSO, ZeClinics and Danilo Maddalo Lab Head ONC Pharmacology, Novartis Institutes for BioMedical Research discuss the latest regarding CRISPR delivery challenges and applications within Pharma.
Experts
| |
Danilo Maddalo |
[inlinead]
| Have Your Say Rate this feature and give us your feedback in the comments section below |
